
    
      Part 1: This is a first-in-human (FIH), double-blind (neither the researchers nor the
      participants know what treatment the participant is receiving), randomized (study medication
      assigned to participants by chance), placebo-controlled (an inactive substance; a pretend
      treatment [with no drug in it] that is compared in a clinical trial with a drug to test if
      the drug has a real effect) study. Part 1 includes healthy adult participants, divided into 3
      panels (Panel 1, 2 and 3) and in Part 2 adult Chronic Hepatitis B Participants will be
      included, in Sessions VIII to XI and Optional Sessions A-B-C (Panel 4). The study will
      consists of screening phase (part 1: [less than or equal to <=28 days before the first intake
      of study drug; part 2: [<=56 to greater than or equal to {>=} 20 days before the first intake
      of study drug), Treatment Phase (multiple dose phase in part 1: Day -1 up to 12 or 19 days;
      part 2: up to 4 weeks) and Follow up Phase (part 1: 30-35 days after last study drug intake
      or after dropout; part 2: up to week 8 after actual end of study drug treatment).
      Participants' safety will be evaluated throughout the study.
    
  